Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency
This study is ongoing, but not recruiting participants.
Study NCT00680446   Information provided by CSL Limited

First Received on May 16, 2008.   Last Updated on March 11, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Primary Immune Deficiency
Additional conditions recognized in this trial
Immunologic Deficiency Syndromes
More general conditions related to this trial
Immune System Diseases
Interventions listed in this trial
Immunoglobulin G (Ig NextGen 16%)
Additional drug interventions recognized in this trial
Antibodies
Immunoglobulin G
Immunoglobulins
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
CSL Limited


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services